Efficacy of Treatment of Postpartum Anaemia With Intravenous Iron Versus Oral Iron in a Tertiary Hospital in South East, Nigeria.

NCT ID: NCT07110935

Last Updated: 2025-08-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

290 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-13

Study Completion Date

2019-02-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:Anaemia is a condition of public health importance.Iron deficiency anaemia is the most common cause of anaemia in pregnancy.Postpartum anaemia poses a significant role for postpartum morbidity and mortality and should be treated.Postpartum iron deficiency anaemia warrants greater attention and higher quality of care.Oral iron treatment has been considered the standard of care.

However,parenteral iron treatment is expected to be advantageous in cases where oral iron therapy is not possible.As a result,there is increased interest in parenteral iron therapy.

Objectives:To determine the effect of treatment of postpartum anaemia with intravenous versus oral iron therapy at Federal Medical Centre,Umuahia.

Materials and Method:This study is a prospective randomized controlled study carried out in department of Obstetric and Gynaecology, Federal Medical Centre,Umuahia,the capital of Abia State,South-east, Nigeria. The study population comprised of postpartum women with mild to moderate anaemia within 48 hours of delivery who were randomized into two groups.One group will be given oral iron therapy and the other intravenous iron dextran.Response and comparative effects of treatment using either route of administration were assessed at 6 weeks postpartum.The biodata,obstetric characteristics and haemoglobin estimation of the respondents were recorded on a structured study proforma.The data obtained from the study was analyzed with the statistical package for the social sciences(SPSS) software.Continuous variables obtained from this study were expressed as mean and standard deviation while categorical variables were summarized using frequency and percentages.Association between categorical variables were done using chi square.P-value less than 0.05 was taken as significant.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postpartum Anaemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

One hundred and forty five women who picked "i" were assigned intravenous iron therapy group

Group Type EXPERIMENTAL

intravenous iron

Intervention Type DRUG

intravenous iron dextran

One hundred and forty five women who picked "o" were assigned oral iron therapy group

Group Type ACTIVE_COMPARATOR

oral iron

Intervention Type DRUG

oral iron(ferrous Sulphate)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intravenous iron

intravenous iron dextran

Intervention Type DRUG

oral iron

oral iron(ferrous Sulphate)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women who have vaginal delivery of singleton baby and are seen within 48hours of childbirth
* Women with mild and moderate anaemia
* Women who gave their consent to participate in the study.

Exclusion Criteria

* Women with severe anaemia
* Women with multiple pregnancy
* Women with genotype HbSS
* Women with HIV infection
* Women who delivered by caesarean section
* Women with co-morbidity like hypertensive disorders, renal pathology
* Women who decline consent after adequate counseling.
* Previous and current history of adverse reaction to iron dextran
Minimum Eligible Age

20 Years

Maximum Eligible Age

39 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Federal Teaching Hospital Abakaliki

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Assumpta Nnenna Nweke

Dr Assumpta Nnenna Nweke

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Federal Medical Centre , Umuahia

Umuahia, Abia State, Nigeria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Nigeria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FMC/QEH/G.596/Vol.10/266

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment of Iron Deficiency Anemia With Pregnancy
NCT02005588 COMPLETED EARLY_PHASE1